Apodex Offers Free AI Drug Research Services

Oct 8, 2026
Apodex is offering small and midsize drug developers free access to AI agents, computing resources and biomedical evidence for research.

Apodex is offering small and midsize drug developers free access to AI agents, computing resources and biomedical evidence, the company said in a press release. Its services cover clinical trial forecasting, drug repurposing and reformulation, drug interaction analysis and safety assessments.

The Clinical Trial Forecasting Lab estimates whether an ongoing trial will meet its primary endpoint and provides supporting evidence. Apodex locks each forecast before results become public and then compares it with the reported outcome. More than 600 forecasts are available.

The services are available through Apodex's drug research website. Companies must agree to terms before work begins, and the outputs are based on public information rather than medical or investment advice.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.